Related Experiment Video

Updated: May 6, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K

Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and

Jonathan W Waks1, Peter J Zimetbaum

  • 1Department of Cardiovascular Diseases, Beth Israel Deaconess Medical Center, 185 Pilgrim Avenue, Baker 4, Boston, MA 02215, USA.

Expert Review of Cardiovascular Therapy
|October 24, 2013
PubMed

Insights

Dabigatran etexilate, a novel oral anticoagulant, offers advantages over warfarin for preventing thromboembolism in atrial fibrillation. The RE-LY trial showed dabigatran 150 mg was superior, while 110 mg was equally effective with less bleeding.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Dabigatran etexilate, a direct thrombin inhibitor, marked a significant advancement in anticoagulant therapy for atrial fibrillation.
  • Unlike warfarin, dabigatran offers a rapid onset, short half-life, and requires no routine monitoring or dietary adjustments.

Purpose of the Study:

  • To compare the efficacy and safety of two dabigatran doses (110 mg and 150 mg twice daily) against adjusted-dose warfarin.
  • To evaluate dabigatran's effectiveness in thromboembolic prophylaxis for patients with non-valvular atrial fibrillation and stroke risk factors.

Main Methods:

  • The RE-LY trial randomized patients with non-valvular atrial fibrillation to receive either dabigatran (110 mg or 150 mg BID) or warfarin.
  • Outcomes assessed included stroke, systemic embolism, and major bleeding events.

Main Results:

  • Dabigatran 150 mg twice daily demonstrated superior stroke/systemic embolism reduction compared to warfarin, with similar major bleeding rates.
  • Dabigatran 110 mg twice daily showed comparable efficacy to warfarin for stroke/systemic embolism prevention but with significantly less major bleeding.
  • Both dabigatran doses were well-tolerated, though optimal dosing and safety in specific populations like the elderly or renally impaired remain subjects of discussion.

Conclusions:

  • Dabigatran provides effective and safe anticoagulation for non-valvular atrial fibrillation patients.
  • The 150 mg dose offers enhanced protection against stroke and embolism, while the 110 mg dose provides a favorable balance of efficacy and safety, particularly regarding bleeding risk.
  • Further research is warranted to clarify optimal dabigatran use in elderly patients and those with renal dysfunction.

More Related Videos

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

17.1K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.6K

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
764
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
470